1 citations
,
October 2018 in “InTech eBooks” This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.
21 citations
,
January 2003 in “Seminars in reproductive medicine” This review outlines the underlying pathophysiology and treatment options for the androgen excess and reproductive and metabolic manifestations of polycystic ovary syndrome, but reports no clinical results.
21 citations
,
October 2015 in “Current Drug Targets” This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.
6 citations
,
August 2009 in “Mini-reviews in Medicinal Chemistry” This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.
July 2023 in “University of Debrecen Electronic Archive (University of Debrecen)” This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.
